MedMira Announces Approval of Settlement of Debt

About this update from Medmira Inc.

[{"type":"text","content":"\n\n\n\nHALIFAX, July 24 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,\nNASDAQ: MMIRF) a developer and marketer of rapid diagnostics, announced today\nthat further to the news release issued June 5, 2009, it has received approval\nfrom the TSX Venture Exchange to settle $479,431 of debt through the issuance\nof common shares. The Company will issue 6,849,011 common shares at a price of\n$0.07 per share based on the June 4, 2009 close. Shares issued under this\nagreement will be subject to a four month hold period.\n\n\nAbout MedMira\n\n\nMedMira is a leading developer and manufacturer of flow-through rapid\ndiagnostics. The company's tests provide hospitals, labs, clinics and\nindividuals with reliable, rapid diagnosis for diseases such as HIV and\nhepatitis C in just three minutes. The company's tests are sold under the\nReveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global\nmarkets. MedMira's rapid HIV test is the only one in the world to achieve\nregulatory approvals in Canada, the United States, China and the European\nUnion. MedMira's corporate offices and manufacturing facilities are located in\nHalifax, Nova Scotia, Canada. For more information visit MedMira's website at\nwww.medmira.com.\n\n\nThis news release contains forward-looking statements, which involve risk\nand uncertainties and reflect the company's current expectation regarding\nfuture events. Actual events could materially differ from those projected\nherein and depend on a number of factors including, but not limited to,\nchanging market conditions, successful and timely completion of clinical\nstudies, uncertainties related to the regulatory approval process,\nestablishment of corporate alliances and other risks detailed from time to\ntime in the company quarterly filings.\n\n\nThe TSX Venture Exchange has not reviewed and does not accept\nresponsibility for the adequacy or accuracy of this statement.\n\n\n%SEDAR: 00013053E\n\n\n","length":2040,"tagName":"div"}]

More updates from Medmira Inc.